FDA Grants Full Approval for BALVERSA to Treat Locally Advanced or Metastatic Bladder Cancer with…
Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) approved a supplemental New Drug Application (sNDA) for BALVERSA (erdafitinib) for the treatment…
Read More...
Read More...